Consolidated Statements of Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (3,547,782)	$ (7,287,605)	$ 25,123,901	$ (27,220,171)
Available for sale securities - net unrealized loss	(28,717)	(486)	(28,717)	(486)
Total other comprehensive loss	(28,717)	(486)	(28,717)	(486)
Comprehensive (loss) income	(3,576,499)	(7,288,091)	25,095,184	(27,220,657)
Comprehensive loss attributable to noncontrolling interests	(119,342)	(405,072)	(717,665)	(522,005)
Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (3,457,157)	$ (6,883,019)	$ 25,812,849	$ (26,698,652)